AstraZeneca
must prove claim to cheapest COVID-19 vaccine - MSF
Send a link to a friend
[November 24, 2020]
BRUSSELS (Reuters) - AstraZeneca must prove
its claim that its potential COVID-19 vaccine has the lowest price of
the main candidates so far, non-governmental organisation Medecins Sans
Frontieres (MSF) said on Tuesday, urging the company to make public its
supply contracts.
|
The British firm said on Monday its COVID-19 vaccine was 70%
effective in pivotal trials and could be up to 90% effective, giving
the world's fight against the global pandemic a third new weapon
that can be cheaper to make, easier to distribute and faster to
scale-up than rivals.
AstraZeneca has said it will not profit from sales of its vaccine,
the price of which has been set at about $3 per dose, against at
least four times more for other candidates.
"MSF welcomes AstraZeneca's commitment to sell the vaccine at a
'no-profit' price during the pandemic, but the reality is that it's
an empty promise unless we're able to substantiate these important
claims with data," said Roz Scourse of medical group MSF, also known
as Doctors Without Borders.
The organisation urged AstraZeneca to disclose the contracts signed
with governments for its vaccine, under which there could be clauses
that limit the price until the company declares the end of the
health emergency, which could be as early as July, according to
media reports cited by MSF.
[to top of second column] |
"This means that, after July 2021, AstraZeneca could charge governments and
other purchasers high prices for a vaccine that was entirely funded by the
public," the organisation said, adding the company had received over $1 billion
of public funding for its COVID-19 vaccine candidate.
AstraZeneca had no immediate comment on the matter.
The company has said a COVID-19 vaccine needs to be available globally and
accessible to all who need it, and has expressed its support for a procurement
scheme co-led by the World Health Organization designed to secure rapid and fair
global access to COVID-19 vaccines.
(Reporting by Francesco Guarascio @fraguarascio; additional reporting by
Alistair Smout; Editing by Mark Potter)
[© 2020 Thomson Reuters. All rights
reserved.] Copyright 2020 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.
Thompson Reuters is solely responsible for this content. |